London: German vaccine-maker Curevac has said that its COVID-19 vaccine CVnCoV can remain stable for at least 3 months at 5 degrees Celsius. This would make it easier to distribute with normal refrigeration containers, unlike Pfizer’s vaccine which reportedly requires -70 degrees Celsius.
However, Curevac is not one of the frontrunners in the vaccine race. It hopes to start phase 3 trials by end of the this year. Frontrunners such as Moderna, Pfizer, AstraZeneca and Johnson & Johnson are ahead in the race with some ready to launch the vaccine in a couple of months.
